Iam CBFB-MYH11 Kit
An ultra rapid solution for a one-step differential detection of CBFB-MYH11 Type A, D and E fusion transcripts
Do you want to place an order or request a trial?
Discover More
KIT for Oncohematology Overview
Background
CBFB-MYH11, also known as PEBP2B-MYH11, inv(16), t(16;16) is a recurrent genetic abnormality especially in adult Acute Myeloid Leukemia (10% of all de novo AML). This translocation is also one of the most frequently balanced chromosomal translocations found in patients with therapy-related AML (t-AML). Although this genetic alteration is associated with a good prognosis, 30%-40% of these patients experience relapse and its rapid molecular identification is considered crucial for patients’ management and therapeutic decisions.
Why to choose it
Comprehensive molecular identification of common (Type A) and rare (Type D and E) isoforms of CBFB-MYH11 fusion in a single rapid step.
For use on
Benefits
Identification of positive samples in less than 20 min, starting from extracted RNA
set up
From RNA to result in a one-step solution
Retrotrascription, amplification and data elaboration happen on board the LIAISONTM IAM in a close tube, one-step format.
Internal endogenous control and quality controls are included to allow validation of results
No false positive results and absence of primer dimers
The Analytical Specificity has been established on negative cell line RNA extracted by both the Qiagen RNeasyTM kit and modified TrizolTM.
| Sample type | Replicates | % Analytical Specificity |
|---|---|---|
| Sample typeCell lines | Replicates400 | % Analytical Specificity100% |
| Sample typeNTC | Replicates214 | % Analytical Specificity99,5% |
| Total replicates | Replicates614 | % Analytical Specificity99,8% |
100% concordance with the traditional RT-PCR (Biomed Protocol*, by Van Dongen et al)
*Leukemia. 1999 Dec;13(12):1901-28.
The analysis has been performed on clinical samples using RNA extracted by QiagenTM RNeasyTM kit or modified TRIzolTM protocol and demonstrates a complete concordance with the reference method.
| Sample status | No.Samples | % Agreement with PCR (BIOMED protocol) |
|---|---|---|
| Sample statusCBFB-MYH11 A positive | No.Samples28 | % Agreement with PCR 100% |
| Sample statusCBFB-MYH11 D or E positive | No.Samples9 | % Agreement with PCR 100% |
| Sample statusCBFB-MYH11 negative | No.Samples30 | % Agreement with PCR 100% |
| Total replicates | TotalSamples67 | % Agreement with PCR 100% |
Superior robustness to inhibitors, RNA degradation and suboptimal target quantities
The intrinsic robustness of the enzyme employed in Q-LAMP results in an enhanced robustness versus the classical inhibitor factors of PCR.
Q-LAMP is a very rapid, easy, accurate, convenient and robust method for detection of CBFB-MYH11 translocations
| Q-LAMP | RT-PCR (Biomed) | |
|---|---|---|
| SubjectRNA input | Q-LAMP500 ng/rx robust down to 25 ng/rx | RT-PCR (Biomed)1μg/rx |
| SubjectSteps | Q-LAMP1 | RT-PCR (Biomed)3 |
| SubjectAssay format | Q-LAMPMULTIPLEX | RT-PCR (Biomed)SIMPLEX |
| SubjectControl of reaction | Q-LAMPINTERNAL | RT-PCR (Biomed)EXTERNAL |
| SubjectRobustness | Q-LAMP– to chemical contamination – to PCR inhibitors – to degraded samples |
RT-PCR (Biomed)To chemical contamination |
| SubjectResult interpretation | Q-LAMPOBJECTIVE | RT-PCR (Biomed)SUBJECTIVE |
| SubjectTime to result | Q-LAMP40min | RT-PCR (Biomed)3h 30min |
Ordering info
| Product | Code | Reactions |
|---|---|---|
| Product Iam CBFB-MYH11 (A/D/E) |
Code V36CBFB | Reactions 54 |
Do you want to place an order or request a trial?
Discover MoreOur repository
All the answers you need.
Access our database to find:
instructions for use, safety data sheets,
assay protocols and more.